Free NHS Wegovy for Scottish at-risk patients

In Scotland, the weight-loss jab Wegovy will soon be available free of charge through the NHS. This decision by the Scottish Medicines Consortium (SMC) targets patients who are overweight and have existing cardiovascular disease, placing them at higher risk for heart attacks and strokes. The drug, semaglutide, functions by mimicking a natural hormone that increases feelings of fullness, thereby helping patients manage their weight.

This approval follows a similar rollout in England earlier in the year. Approximately 145,000 patients in Scotland are expected to be eligible for this new treatment. The SMC's guidance specifies that patients with a Body Mass Index (BMI) of 27 or higher, coupled with health conditions that elevate stroke and heart attack risks, can be prescribed the medication. Cardiovascular diseases represent a significant cause of death in Scotland, making preventative treatments like Wegovy crucial.

Experts emphasize that Wegovy's benefits extend beyond simple weight reduction. Clinical trials indicate it can directly improve heart and blood vessel health, reducing the likelihood of future cardiovascular problems. This makes it a vital tool in combating the leading causes of mortality in the country and potentially saving numerous lives.